Novavax Corporate Presentation May 2025 © 2025 NOVAVAX. All rights reserved. Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate strat ...

Company Overview - The company has transitioned from a small biotech firm to a more established organization, launching its first product during the pandemic [3] - The leadership team has undergone significant changes, focusing on enhancing the company's structure and strategy post-Sanofi deal [2][3] Leadership and Team - The current leadership team includes John Jacobs as President and CEO, Jim Kelly as CFO, and Ruxandra Draghia-Akli as EVP and Head of R&D, who recently joined the company [1][2] - The team emphasizes the credentials and expertise of its members, highlighting their qualifications and contributions to the company [2] Strategic Focus - The company's strategy post-Sanofi has been to leverage its technology platform to drive growth and innovation [3] - There is a strong emphasis on adapting the expense profile and operational structure to align with the new strategic direction [3]

Novavax (NVAX) 2025 Conference Summary Company Overview - **Company**: Novavax (NVAX) - **Event**: 2025 Bank of America Healthcare Conference - **Date**: May 14, 2025 Key Points Industry and Company Developments - Novavax has transitioned from a small biotech to a more structured organization post-pandemic, focusing on leveraging its technology platform for growth through partnerships and R&D [3][4] - The company has launched four new R&D programs in the last quarter, indicating a robust pipeline for future growth [3] Financial Guidance and Performance - Novavax raised its revenue guidance based on BLA milestones from its partnership with Sanofi, with expectations of breakeven and profitability as early as 2027 [6][7] - The company anticipates receiving $2.25 billion in cash from BLA approvals and license transfers to Sanofi, which includes a $1.75 billion milestone and two $25 million license transfers [39][40] Regulatory and Approval Pathways - Novavax is in discussions with the FDA regarding post-marketing commitments, which are expected to be less stringent than requirements, allowing for potential approval in the near term [9][10][14] - The company has a robust dataset from a placebo-controlled trial involving 30,000 individuals for its COVID vaccine, Nuvaxavid, supporting its approvability [17][18] Market Dynamics and Vaccine Strategy - The company is observing a shift in consumer choice towards vaccines with better tolerability, which could favor Novavax's offerings [58][59] - The COVID vaccine market is expected to grow significantly, with Novavax aiming to capture a substantial share through its innovative technology and partnerships [77] Partnerships and Collaborations - Novavax has expanded its partnership with Sanofi and signed new agreements with top pharmaceutical companies to explore the utility of its Matrix M adjuvant in various vaccine platforms [4][48][50] - The updated agreement with Takeda includes a $20 million upfront payment and a shift to a traditional royalty model, enhancing the partnership's economic viability [44][46] Future Outlook - The company is focused on reducing liabilities and costs, aiming for an 80-85% reduction in R&D and SG&A expenses by 2027, which will enable a stronger focus on value creation [76][77] - Novavax is positioned to capitalize on the growing vaccine market, projected to increase from $50 billion to $75 billion, leveraging its technology across multiple vaccine categories [77] Additional Insights - The company is actively monitoring the evolving landscape of COVID variants and the need for seasonal vaccine updates, which is critical for maintaining market relevance [26][28] - Novavax's strategy includes developing combination vaccines and exploring new markets, such as oncology, to diversify its product offerings [48][52] Conclusion - Novavax is strategically positioned for growth through innovative partnerships, a strong pipeline, and a focus on cost reduction, aiming to capture a significant share of the expanding vaccine market while ensuring product safety and efficacy.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NVAX over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Novavax (NVAX) reported first-quarter 2025 earnings of $2.93 per share, which beat the Zacks Consensus Estimate of 71 cents. In the year-ago quarter, the company reported a loss of $1.05 per share.Quarterly revenues totaled $667 million compared with $94 million in the year-ago period. The reported figure beat the Zacks Consensus Estimate of $212 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)More on NVAX’s EarningsNovavax recorded $622 million in product sales compared wit ...

On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.Higher product sales for the first quarter of 2025 were primarily due to $603 million of revenue recognized with the termination of two Advance Purchase Agreements (APA) and related to cash received in prior years. $45 million of Licensing, Royalties, & Other Revenue in the first quarter of 2025 was higher than the prior year due to $40 million of San ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 312.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.75 per share when it actually produced a loss of $0.51, delivering a surprise of 32%.Over the last four quarters, the company has surpasse ...

Novavax (NVAX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, and welcome to Novavax First Quarter twenty twenty five Financial Results and Operational Highlights Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I'd now like to turn the conference over to Luis Sannai, Vice President, Investor Relations. Please go ahead. Speaker1 Good morning, and thank ...

First Quarter 2025 Financial Results and Operational Highlights May 8, 2025 © 2025 NOVAVAX. All rights reserved. Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters ...